Form 4: Cyclo Therapeutics COO Jeffrey Tate Acquires Stock Options
Sentiment:
SEC Form 4 Filing
Jeffrey Tate, COO of Cyclo Therapeutics, acquired stock options on June 3, 2024.
Summary
- Jeffrey Tate, the Chief Operating Officer of Cyclo Therapeutics, Inc., acquired 110,732 stock options on June 3, 2024.
- The options have an exercise price of $1.28.
- The options vest over a one-year period in equal quarterly installments and expire on June 3, 2034.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard disclosure of stock option acquisition by a company executive.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by the COO could potentially align his interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of the stock option transaction. |
| 06/03/2034 | Expiration date of the stock options. |
| 06/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.